TVTX insider trading
HealthcareTravere Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Company website: www.travere.com
TVTX insider activity at a glance
FilingIQ tracks 558 insider transactions for TVTX in filings since Dec 4, 2020. The most recent transaction is dated Sep 17, 2026.
Across the full history, 0 open-market purchases
and 321 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on TVTX insider trades is 59.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest TVTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for TVTX?
- FilingIQ tracks 558 Form 4 insider transactions for TVTX (Travere Therapeutics, Inc.), covering filings from Dec 4, 2020 onwards. 71 of those are dated within the last 90 days.
- Are TVTX insiders net buyers or net sellers?
- Across the full Form 4 history for TVTX, 0 transactions (0%) were open-market purchases and 321 (58%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does TVTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is TVTX in?
- Travere Therapeutics, Inc. (TVTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $2.53B.
Methodology & sources
Every TVTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.